Cyclacel Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Cyclacel Pharma (CYCC) Announces Share and Warrant Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cyclacel Pharma (CYCC) Regains Nasdaq Compliance
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cyclacel Pharma (CYCC) Files $100M Mixed Shelf
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
22 Stocks Moving in Friday s Pre-Market Session
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data
WASHINGTON (dpa-AFX) - Today s Daily Dose brings you news about BioCryst s update on its investigational broad-spectrum antiviral Galidesivir in the treatment of COVID-19, a $7 million strategic investment by Acorn Bioventures in Cyclacel Pharma, Supernus phase III study results of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder, and Spectrum s progress with Poziotinib for non-small cell lung cancer.
Read on.
1. BioCryst Not to Pursue COVID-19 indication for antiviral Galidesivir
Shares of BioCryst Pharmaceuticals Inc. (BCRX) dropped more than 8% on Tuesday after the company announced that it will no longer be pursuing the COVID-19 indication for its investigational broad-spectrum antiviral Galidesivir.